IMPACT study of Zephyr Endobronchial Valves in emphysema published in American Journal of Respiratory and Critical Care Medicine- Pulmonx Corp

Positive results from the IMPACT study demonstrate that patients with homogeneous emphysema benefit from treatment with Pulmonx Corporation�s proprietary Zephyr Endobronchial Valves (EBV), according to a new study published online in the American Journal of Respiratory and Critical Care Medicine. Patients pre-selected with the Chartis System and treated with EBV experienced clinically meaningful improvements in lung function, exercise tolerance, and quality of life compared to the control group. These data indicate that EBV therapy can benefit substantially more patients than previously believed.

Three-month results from the IMPACT study showed that patients with homogeneous emphysema and little or no collateral ventilation (assessed using the Chartis System) treated with the Zephyr EBV experienced a 17 percent improvement in FEV1 compared to the control group. EBV-treated patients also experienced improved exercise tolerance, with a 40-meter increase over the control group in the Six Minute Walk Test (6MWD), and improved quality of life, with a 10-point improvement in the St. Georges Respiratory Questionnaire (SGRQ) score over the control group. The results also showed that 97 percent of EBV subjects experienced target lobe volume reduction, indicating effective occlusion of the target lobe following EBV placement.

See: "Endobronchial Valve Therapy in Patients with Homogeneous Emphysema: Results from the IMPACT Study" Arschang Valipour et al. Am J Respir Crit Care Med. First published online 31 Aug 2016 as DOI: 10.1164/rccm.201607-1383OC